Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.
Research
Tuberculosis
basic science
blue skies research
fundamental
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
07
03
2022
accepted:
08
03
2022
pubmed:
19
3
2022
medline:
15
12
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
Investments into 'Blue Skies' fundamental TB research in low- and middle-income countries (LMICs) have not been forthcoming. We highlight why blue skies research will be essential for achieving global TB control and eradicating TB. We review the historical background to early TB discovery research and give examples of where investments into basic science and fundamental 'blue skies research' are delivering novel data and approaches to advance diagnosis, management and holistic care for patients with active and latent TB infection. The COVID-19 pandemic has shown that making available adequate funding for priority investments into 'Blue skies research' to delineate scientific understanding of a new infectious diseases threat to global health security can lead to rapid development and rollout of new diagnostic platforms, treatments, and vaccines. Several advances in new TB diagnostics, new treatments and vaccine development are underpinned by basic science research. Blue Skies research is required to pave the way for a personalized medicine approach for management of TB and other Respiratory Tract Infections and preventing long-term functional disability. Transfer of skills and resources by wealthier nations is required to empower researchers in LMICs countries to engage in and lead Blue Skies research.
Identifiants
pubmed: 35301102
pii: S1201-9712(22)00150-3
doi: 10.1016/j.ijid.2022.03.012
pmc: PMC8920086
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S69-S74Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors have an interest in TB. All authors declare no conflicts of interest.
Références
Curr Epidemiol Rep. 2021;8(2):33-45
pubmed: 33842192
Int J Infect Dis. 2022 Nov;124 Suppl 1:S90-S103
pubmed: 35245659
mBio. 2021 May 20;12(3):
pubmed: 34016711
PLoS One. 2012;7(7):e42479
pubmed: 22848764
Comput Struct Biotechnol J. 2021 Jul 30;19:4284-4299
pubmed: 34429848
Lancet Infect Dis. 2018 Jul;18(7):e199-e210
pubmed: 29580818
Lancet Respir Med. 2020 Apr;8(4):337-340
pubmed: 32113574
J Biomed Discov Collab. 2008 Feb 29;3:3
pubmed: 18312612
Eur Respir J. 2019 Mar 18;53(3):
pubmed: 30886024
Eur Respir J. 2021 Nov 25;58(5):
pubmed: 33875495
PLoS One. 2022 Jan 24;17(1):e0262545
pubmed: 35073339
Annu Rev Med. 2022 Jan 27;73:55-64
pubmed: 34637324
Trop Med Int Health. 2011 Jan;16(1):79-83
pubmed: 21342371
Eur Respir J. 2022 Sep 15;60(3):
pubmed: 35169026
Annu Rev Genomics Hum Genet. 2008;9:403-33
pubmed: 18593304
Front Immunol. 2020 Oct 08;11:566608
pubmed: 33117351
Lancet Infect Dis. 2016 Apr;16(4):e47-63
pubmed: 27036359
Int J Infect Dis. 2021 Sep;110:54-61
pubmed: 34216733
PLoS Biol. 2018 Sep 25;16(9):e3000037
pubmed: 30252891
Lancet Infect Dis. 2015 Jan;15(1):11-3
pubmed: 25477021
Front Microbiol. 2021 Oct 06;12:750124
pubmed: 34691001
Front Immunol. 2022 Jan 31;13:830497
pubmed: 35173740
Lancet Glob Health. 2021 Dec;9(12):e1679-e1687
pubmed: 34798027
Emerg Microbes Infect. 2021 Dec;10(1):1217-1218
pubmed: 34036874
Clin Infect Dis. 2015 Nov 1;61(9):1432-8
pubmed: 26219693
Infect Immun. 2004 Nov;72(11):6324-9
pubmed: 15501761
Nat Rev Drug Discov. 2018 Sep;17(9):607-608
pubmed: 29567994
Immunol Lett. 2022 Feb;242:27-36
pubmed: 35007662
Lancet Infect Dis. 2018 Jul;18(7):e183-e198
pubmed: 29580819
Lancet Respir Med. 2016 Apr;4(4):249-51
pubmed: 27016869
Lancet. 2012 Mar 24;379(9821):1077-8
pubmed: 22444391
Clin Microbiol Rev. 2021 Dec 15;34(4):e0006421
pubmed: 34612662
Clin Med (Lond). 2010 Oct;10(5):450-3
pubmed: 21117375
Nat Rev Drug Discov. 2015 Aug;14(8):511-2
pubmed: 26184493
Methods Mol Biol. 2021;2314:579-593
pubmed: 34235671
Arch Biochem Biophys. 2022 Feb 15;716:109118
pubmed: 34999018
Curr Opin Pulm Med. 2021 May 1;27(3):205-209
pubmed: 33629969
JCI Insight. 2022 Feb 8;7(3):
pubmed: 34990408
Lancet. 2019 Mar 30;393(10178):1331-1384
pubmed: 30904263
J Infect. 2019 Apr;78(4):261-268
pubmed: 30849440
Int J Infect Dis. 2019 Mar;80S:S62-S67
pubmed: 30685590
J Infect Dis. 2019 Apr 19;219(10):1518-1524
pubmed: 30590592
Clin Microbiol Infect. 2018 Jun;24(6):604-609
pubmed: 29108952
Semin Immunopathol. 2020 Jun;42(3):315-331
pubmed: 32189035
EBioMedicine. 2022 Mar;77:103886
pubmed: 35183869
Respiration. 2021;100(8):751-763
pubmed: 33401266
BMC Genomics. 2016 Sep 26;17(1):755
pubmed: 27671213
Lancet Respir Med. 2018 Apr;6(4):237-238
pubmed: 29595500
Front Immunol. 2017 Sep 13;8:1134
pubmed: 28955344
Nat Rev Microbiol. 2019 Sep;17(9):533-545
pubmed: 31209399
Lancet Infect Dis. 2022 Apr;22(4):442-444
pubmed: 35248166
J Clin Microbiol. 2022 Mar 16;60(3):e0236221
pubmed: 35170980
Int J Tuberc Lung Dis. 2009 May;13(5):558-68
pubmed: 19383187
Lancet. 2011 Jan 1;377(9759):10-1
pubmed: 21168203
Front Immunol. 2021 Aug 04;12:694680
pubmed: 34421903
Trop Med Int Health. 2010 Mar;15(3):274-6
pubmed: 20070628
Int J Infect Dis. 2017 Mar;56:126-129
pubmed: 27979782
Pathogens. 2022 Jan 21;11(2):
pubmed: 35215073
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4206-4211
pubmed: 30683723
Lancet. 2010 Jun 19;375(9732):2179-91
pubmed: 20488521
Microorganisms. 2021 Oct 26;9(11):
pubmed: 34835346